Adaptimmune Therapeutics Plc - ADR (ADAP) Company Profile & Statistics

Adaptimmune Therapeutics Plc - ADR
ADAP
(Nasdaq - US)
N/A
1.10
-0.10 (-8.33%)
in:usd•As of: May 17, 2024 15:59 UTC -4
Open
1.16
High
1.17
Low
1.10

About Adaptimmune Therapeutics Plc - ADR

CEO

Adrian Rawcliffe

Headquarters

60 jubilee avenue, milton park

abingdon, x0 ox14 4rx, united kingdom

Auditor

KPMG LLP

Employees

449

Share Holders

Website

www.adaptimmune.com

Industry

biotechnology

Sector

health technology

Company Overview

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

Adaptimmune Therapeutics Plc - ADR Statistics

Valuation Measures

Market Capitalization ²	271.50M
Enterprise Value	130.83M
Enterprise Value/EBITDA (ttm)	-0.73
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	12.15
Price to Sales (ttm)	16.13
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-985.47%
Profit Margin (ttm)	-5659.48%
Return on Equity (ttm)	-259.68%
Return on Invested Capital (ttm)	-388.89%
Return on Assets (ttm)	-61.31%

Income Statement

Revenue (ttm)	18.36M
Revenue Per Share (ttm)	N/A
Gross Profit (ttm)	18.36M
EBITDA (ttm)³	-179.83M
Net Income Avi to Common (ttm)	-163.41M
Diluted EPS (ttm)	-0.74

Share Statistics

Beta (5Y Monthly)	2.44
52-Week Change	-16.03%
S&P500 52-Week Change	26.33%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	0.00%
Float ⁴	216.12M
% Held by Insiders	12.44%
% Held by Institutions	31.37%

Balance Sheet

Total Cash (mrq)	143.65M
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	2.81%
Quick Ratio (mrq)	2.85%
Book Value Per Share (mrq)	0.10

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.13
Free Cash Flow (ytd)	-32.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Adaptimmune Therapeutics Plc - ADR

Trade With A Regulated Broker